# K233908: cNeuro cDAT

- Pathway: 510(k) (Traditional)
- Applicant: Combinostics OY
- Decided: Jul 1, 2024 after 202 days
- Product code: LLZ (System, Image Processing, Radiological)
- Device class: 2
- Regulation: 21 CFR 892.2050
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 11 generations back to K010641 (2001). 24 ancestors in all.
No later device cites it as a predicate yet.
0 of 25 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K201103: Xeleris V Processing and Review Systems, GE Healthcare (2020) Summary page 4.

## Indications for use
cNeuro™ cDAT is intended for use by Nuclear Medicine or Radiology practitioners and referring physicians for display, processing, and reporting of Nuclear Medicine Imaging data. cNeuro™ cDAT enables visual evaluation and quantification of ioflupane I 123 (DaTscan™) images. The software enables automated quantification of tracer uptake and comparison with the corresponding tracer uptake in healthy subjects as provided by normal population databases of ioflupane I 123 (DaTscan™) images. cNeuro™ cDAT assists in detection of loss of functional dopaminergic neuron terminals in the striatum, which is correlated with Parkinson disease or Dementia with Lewy Bodies (DLB). cNeuro™ cDAT has not been demonstrated to improve ioflupane I 123 reader performance for distinguishing positive from negative patients. This device should not be used to deviate from ioflupane I 123 dosing and administration instructions. Refer also to ioflupane I 123 prescribing information for instructions.

Source page: https://510kreport.com/device/K233908
Methodology: https://510kreport.com/methodology